On Monday, the American pharmaceutical manufacturer Moderna will apply for immediate approval of its coronary vaccine in both the USA and the EU.
The application will be submitted after a full review of the test results showed an efficiency of 94.1%, the company stated in an announcement.
Moderna’s latest initiative is giving new momentum to the international race to get an approved vaccine on the market, at the same time as the pandemic reaches new heights in both the EU and the USA.
The capacity of American hospitals is at a breaking point, with over 160,000 cases of infection daily and over 1,400 deaths.
Since the COVID-19 virus first appeared in China almost a year ago, 1.4 million people have lost their lives worldwide.
Moderna is right on Pfizer’s heels.
Pfizer and its German partner BioNTech are applying to begin vaccination in the US in December.
In the UK, the health authorities are also considering Pfizer and BioNTech, as well as a vaccine from AstraZeneca.
© NTB Scanpix / #Norway Today